Funding for this research was provided by:
National Institutes of Health (R01 CA227473, R01 CA158167, K24CA172123, R01 CA166376, P50 CA121974)
National Center for Advancing Translational Sciences (KL2 TR000140)
Melanoma Research Alliance (308721)
American Cancer Society (30157-RSG-16-216-01-TBG)
Text and Data Mining valid from 2019-07-30
Received: 20 March 2019
Accepted: 18 July 2019
First Online: 30 July 2019
Ethics approval and consent to participate
: The study was approved by the Yale University Institutional Review Board and done in accordance with international standards of good practice. All patients were provided written informed consent at enrollment.
: Not applicable.
: H.K. reports research grants from Merck, Bristol-Myers Squibb, and Apexigen during the conduct of the study, and personal fees from Regeneron, Alexion, Prometheus, Corvus, Nektar, Biodesix, Roche-Genetech, Pfizer, Iovance, Immunocore, and Celldex, outside of the submitted work. S.G. reports consulting work for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, and Spectrum. All remaining authors have declared no competing interests.